Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

  • Shunichi Sugawara
  • , Masashi Kondo
  • , Toshihide Yokoyama
  • , Toru Kumagai
  • , Makoto Nishio
  • , Koichi Goto
  • , Kazuhiko Nakagawa
  • , Takashi Seto
  • , Nobuyuki Yamamoto
  • , Kentarou Kudou
  • , Takayuki Asato
  • , Pingkuan Zhang
  • , Yuichiro Ohe

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology